Internal Medicine Alert – June 30, 2025

Are Weight Gain and Mental Health Bidirectionally Connected?

In an adult population-based cohort study over four years, researchers found that both emotional eating and body dissatisfaction independently mediate the relationships between mental health factors and body mass index trajectories.

CT Coronary Artery Calcium Progression After an Initial Score of Zero

A large Korean study of asymptomatic subjects undergoing more than one computed tomography (CT) coronary calcium scoring scan as part of an employment-based health screening has shown that most had scores of 0, and that during a maximum follow-up of 12 years, the majority stayed at 0 on a repeat scan. Also, in those with a coronary artery calcium score of 0 initially, clinically significant scores (> 100) were only found in 4% of scans at 10-year follow-up.

New Injectable Cholesterol-Lowering Drug Trial

A comparison of inclisiran therapy to placebo and ezetimibe therapy over six months in primary prevention patients at low risk of atherosclerotic cardiovascular disease and not taking lipid-lowering therapy has shown that inclisiran subcutaneously every six months reduces low-density lipoprotein cholesterol more than ezetimibe and is comparable to the reported results of high-dose statins taken daily.

24-Hour Activity Rhythms and Amyloid-β Deposition in the Brain

This study of dementia-free adults found that greater variability of the 24-hour activity rhythm (greater during the daytime as well as during sleep time) with fragmentation of sleep predicted increased deposition of amyloid-β (Aβ), especially in apolipoprotein E 4 (APOE4) carriers.

Telisotuzumab Vedotin-tlly (Emrelis)

The U.S. Food and Drug Administration has granted accelerated approval of telisotuzumab vedotin-tilly, a first-in-class c-mesenchymal-epithelial transition factor-directed antibody and a microtubule inhibitor conjugate for the treatment of locally advanced or metastatic, non-squamous non-small cell lung cancer.